Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400503 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT01400503 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 60 participants.
The verdict
NCT01400503, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of siltuximab in patients with multicentric Castleman's disease (MCD).
Interventions
- DRUG Siltuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-04-01 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01400503
The ClinicalTrials.gov registry entry for NCT01400503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Siltuximab is the first listed.
NCT01400503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01400503 about?
NCT01400503 is a clinical study titled "A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease". The purpose of this study is to evaluate the long-term safety of siltuximab in patients with multicentric Castleman's disease (MCD).
What is the current status of trial NCT01400503?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2011-04-01. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT01400503?
The interventions under investigation include: Siltuximab (DRUG).
Who is sponsoring clinical trial NCT01400503?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.